LOGIN  |  REGISTER
Recursion
Recursion

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

August 26, 2025 | Last Trade: US$11.65 0.19 -1.60

CAMBRIDGE, Mass. / Aug 26, 2025 / Business Wire / Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in Boston and New York City.

  • Citi's 2025 Biopharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025, at 1:00pm ET
  • Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3, 2025, at 8:00am ET
  • Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Monday, September 8, 2025, at 4:50pm ET
  • Baird 2025 Global Healthcare Conference: Fireside chat on Tuesday, September 9, 2025, at 3:10pm ET
  • H.C. Wainwright 27th Annual Global Investment Conference: Corporate presentation on Wednesday, September 10, 2025, at 10:00am ET

A live webcast of each conference event can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page